Is Banking of HLA-typed iPS Cell Lines for Cell-Based Therapy Practical, Sustainable and Commercially Feasible?
The first pilot clinical study of cell-based therapy using human induced pluripotent stem cell (iPSC) has started in Japan, and banking of HLA-typed iPSC lines is proposed for practical application of the iPSC-based therapy.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>